KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Assets: 2009-2024

Historic Assets for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to $39.3 billion.

  • Teva Pharmaceutical Industries' Assets fell 4.55% to $39.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $39.9 billion, marking a year-over-year decrease of 4.55%. This contributed to the annual value of $39.3 billion for FY2024, which is 9.55% down from last year.
  • As of FY2024, Teva Pharmaceutical Industries' Assets stood at $39.3 billion, which was down 9.55% from $43.5 billion recorded in FY2023.
  • In the past 5 years, Teva Pharmaceutical Industries' Assets ranged from a high of $50.6 billion in FY2020 and a low of $39.3 billion during FY2024.
  • Moreover, its 3-year median value for Assets was $43.5 billion (2023), whereas its average is $42.3 billion.
  • Data for Teva Pharmaceutical Industries' Assets shows a maximum YoY declined of 11.88% (in 2020) over the last 5 years.
  • Over the past 5 years, Teva Pharmaceutical Industries' Assets (Yearly) stood at $50.6 billion in 2020, then declined by 5.87% to $47.7 billion in 2021, then dropped by 7.67% to $44.0 billion in 2022, then fell by 1.21% to $43.5 billion in 2023, then declined by 9.55% to $39.3 billion in 2024.